All stock lists
C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
Healthcare · Biotechnology
3.00-0.06 (-1.96%)
Insider Score
––Not scored
CCCC Insider Score
Insiders here have filed 4 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
CCCC Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 |
| Revenue | 6.64 M | 6.15 M | 11.02 M | 11.23 M | 6.46 M |
| Revenue Growth (YoY) | 2.75 % | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| SG&A Expense | 8.59 M | 9.33 M | 9.18 M | 8.92 M | 8.77 M |
| R&D Expense | 24.47 M | 24.61 M | 24.98 M | 25.99 M | 26.20 M |
| Operating Expenses | 33.06 M | 33.94 M | 34.16 M | 34.91 M | 34.96 M |
| Operating Income | -26.42 M | -27.79 M | -23.14 M | -23.68 M | -28.50 M |
| Pretax Income | -23.64 M | -25.13 M | -20.36 M | -32.17 M | -26.02 M |
| Tax Provision | — | — | — | — | — |
| Net Income | -23.64 M | -25.13 M | -20.49 M | -32.17 M | -26.02 M |
| EPS (Basic) | -0.18 | -0.20 | -0.18 | -0.44 | -0.37 |
| EPS (Diluted) | -0.18 | -0.20 | -0.18 | -0.44 | -0.37 |
| Shares Outstanding | 130.70 M | 126.07 M | 116.78 M | 72.56 M | 71.01 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.